Cpmg Inc Reata Pharmaceuticals Inc Transaction History

Cpmg Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $17 Million - $30.8 Million	-166,666 Reduced 5.44%	2,896,901 $358 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $3 Million - $8.76 Million	40,218 Added 1.33%	3,063,567 $626 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $76.44 $5.4 Million - $8.47 Million	110,826 Added 3.81%	3,023,349 $170 Million
Q2 2018 Oct 02, 2018	SELL	$19.94 - $40.96 $33.8 Million - $69.3 Million	-1,692,857 Reduced 36.76%	2,912,523 $102 Million
Q2 2018 Aug 14, 2018	BUY	$19.94 - $40.96 $33.8 Million - $69.3 Million	1,692,857 Added 58.12%	4,605,380 $161 Million
Q1 2018 Oct 02, 2018	SELL	$20.0 - $30.19 $33.9 Million - $51.1 Million	-1,692,857 Reduced 36.76%	2,912,523 $59.7 Million
Q1 2018 May 15, 2018	BUY	$20.0 - $30.19 $33.9 Million - $51.1 Million	1,692,857 Added 58.12%	4,605,380 $94.5 Million
Q4 2017 Oct 02, 2018	SELL	$22.39 - $33.27 $37.9 Million - $56.3 Million	-1,692,857 Reduced 36.76%	2,912,523 $82.5 Million
Q4 2017 Feb 14, 2018	BUY	$22.39 - $33.27 $103 Million - $153 Million	4,605,380	4,605,380 $130 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Cpmg Inc, based on Form 13F filings with the SEC.

Stay updated on Cpmg Inc with notifications on news.